16.76
-0.69 (-3.95%)
| Penutupan Terdahulu | 17.45 |
| Buka | 17.17 |
| Jumlah Dagangan | 2,613,898 |
| Purata Dagangan (3B) | 2,846,139 |
| Modal Pasaran | 1,756,233,216 |
| Harga / Pendapatan (P/E Ke hadapan) | 4.06 |
| Harga / Jualan (P/S) | 0.800 |
| Harga / Buku (P/B) | 1.62 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2026 |
| Margin Keuntungan | -11.12% |
| Margin Operasi (TTM) | -40.33% |
| EPS Cair (TTM) | -2.64 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 80.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 248.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 118.73% |
| Nisbah Semasa (MRQ) | 4.02 |
| Aliran Tunai Operasi (OCF TTM) | -547.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -741.26 M |
| Pulangan Atas Aset (ROA TTM) | -2.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -23.61% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Sarepta Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -1.60 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.42% |
| % Dimiliki oleh Institusi | 96.33% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 38.00 (Wells Fargo, 126.73%) | Beli |
| Median | 21.50 (28.28%) | |
| Rendah | 5.00 (HC Wainwright & Co., -70.17%) | Jual |
| Purata | 21.50 (28.28%) | |
| Jumlah | 2 Beli, 2 Jual | |
| Harga Purata @ Panggilan | 17.97 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 10 Mar 2026 | 9.00 (-46.30%) | Jual | 17.66 |
| HC Wainwright & Co. | 02 Mar 2026 | 5.00 (-70.17%) | Jual | 16.32 |
| 27 Jan 2026 | 5.00 (-70.17%) | Jual | 22.17 | |
| Wells Fargo | 27 Feb 2026 | 38.00 (126.73%) | Beli | 16.76 |
| Wedbush | 23 Jan 2026 | 34.00 (102.86%) | Beli | 21.13 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ESTEPAN IAN MICHAEL | - | 16.98 | -5,795 | -96,711 |
| RODINO-KLAPAC LOUISE | - | 16.98 | -5,884 | -97,874 |
| ROTHFUSS CRISTIN | - | 16.98 | -1,238 | -21,300 |
| WONG RYAN HO-YAN | - | 16.98 | -725 | -12,195 |
| Jumlah Keseluruhan Kuantiti Bersih | -13,642 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -228,080 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 16.98 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ESTEPAN IAN MICHAEL | Pegawai | 09 Mar 2026 | Dibuang (-) | 1,619 | 17.64 | 28,559 |
| RODINO-KLAPAC LOUISE | Pegawai | 09 Mar 2026 | Dibuang (-) | 1,399 | 17.64 | 24,678 |
| ROTHFUSS CRISTIN | Pegawai | 09 Mar 2026 | Dibuang (-) | 830 | 17.64 | 14,641 |
| WONG RYAN HO-YAN | Pegawai | 09 Mar 2026 | Dibuang (-) | 275 | 17.64 | 4,851 |
| RODINO-KLAPAC LOUISE | Pegawai | 02 Mar 2026 | Dibuang (-) | 4,485 | 16.32 | 73,195 |
| ESTEPAN IAN MICHAEL | Pegawai | 02 Mar 2026 | Dibuang (-) | 4,176 | 16.32 | 68,152 |
| WONG RYAN HO-YAN | Pegawai | 02 Mar 2026 | Dibuang (-) | 450 | 16.32 | 7,344 |
| ROTHFUSS CRISTIN | Pegawai | 02 Mar 2026 | Dibuang (-) | 408 | 16.32 | 6,659 |
| RODINO-KLAPAC LOUISE | Pegawai | 01 Mar 2026 | Pelaksanaan pilihan | 8,125 | - | - |
| ESTEPAN IAN MICHAEL | Pegawai | 01 Mar 2026 | Pelaksanaan pilihan | 8,125 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |